Publications

Oleg Akilov

Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz SM, Mei MG, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LDS, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Y, O'Connor OA. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021 Jan 15; doi: 10.1158/1078-0432.CCR-20-3706. PubMed PMID: 33451977.
Kruglov O, Wu X, Hwang ST, Akilov OE. The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. Blood Adv. 2020 Oct 13;4(19):4788-4797. doi: 10.1182/bloodadvances.2020002049. PubMed PMID: 33017467; PMCID: PMC7556155.
Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget. 2019 May 3;10(33):3104-3113. doi: 10.18632/oncotarget.5742. PubMed PMID: 31139323; PMCID: PMC6517103.
Raychaudhuri S, Rahvar M, Jedrych J, Karunamurthy A, Kruglov O, Rakfal S, Kane K, Akilov OE. Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor D'Emblée. Am J Dermatopathol. 2018 Nov;40(11):836-840. doi: 10.1097/DAD.0000000000001188. PubMed PMID: 29794483.

<< Investigators Search

Top